Pbx proteins in Cryptococcus neoformans cell wall remodeling and capsule assembly

Pardeep Kumar
Washington University School of Medicine in St. Louis

Christian Heiss
University of Georgia

Felipe H. Santiago-Tirado
Washington University School of Medicine in St. Louis

Ian Black
University of Georgia

Parastoo Azadi
University of Georgia

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Kumar, Pardeep; Heiss, Christian; Santiago-Tirado, Felipe H.; Black, Ian; Azadi, Parastoo; and Doering, Tamara L., "Pbx proteins in Cryptococcus neoformans cell wall remodeling and capsule assembly." Eukaryotic Cell. 13,5. 560-571. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/2922

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
Pardeep Kumar, Christian Heiss, Felipe H. Santiago-Tirado, Ian Black, Parastoo Azadi, and Tamara L. Doering
Pbx Proteins in Cryptococcus neoformans
Cell Wall Remodeling and Capsule Assembly

Pardeep Kumar, Christian Heiss, Felipe H. Santiago-Tirado, Ian Black, Parastoo Azadi and Tamara L. Doering
Eukaryotic Cell 2014, 13(5):560. DOI: 10.1128/EC.00290-13.
Published Ahead of Print 28 February 2014.

Updated information and services can be found at:
http://ec.asm.org/content/13/5/560

These include:
Supplemental material

This article cites 69 articles, 35 of which can be accessed free at:
http://ec.asm.org/content/13/5/560#ref-list-1

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»

Information about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtml
To subscribe to another ASM Journal go to: http://journals.asm.org/site/subscriptions/
Pbx Proteins in Cryptococcus neoformans Cell Wall Remodeling and Capsule Assembly

Pardeep Kumar, a Christian Heiss, b Felipe H. Santiago-Tirado, a Ian Black, b Parastoo Azadi, b Tamara L. Doering a

Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA a; Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA b

The cryptococcal capsule is a critical virulence factor of an important pathogen, but little is known about how it is associated with the cell or released into the environment. Two mutants lacking PBX1 and PBX2 were found to shed reduced amounts of the capsule polysaccharide glucuronoxylomannan (GXM). Nuclear magnetic resonance, composition, and physical analyses showed that the shed material was of normal mass but was slightly enriched in xylose. In contrast to previous reports, this material contained no glucose. Notably, the capsule fibers of pbxΔ mutant cells grown under capsule-inducing conditions were present at a lower than usual density and were loosely attached to the cell wall. Mutant cell walls were also defective, as indicated by phenotypes including abnormal cell morphology, reduced mating filamentation, and altered cell integrity. All observed phenotypes were shared between the two mutants and exacerbated in a double mutant. Consistent with a role in surface glycan synthesis, the Pbx proteins localized to detergent-resistant membrane domains. These results, together with the sequence motifs in the Pbx proteins, suggest that Pbx1 and Pbx2 are redundant proteins that act in remodeling the cell wall to maintain normal cell morphology and precursor availability for other glycan synthetic processes. Their absence results in aberrant cell wall growth and metabolic imbalance, which together impact cell wall and capsule synthesis, cell morphology, and capsule association. The surface changes also lead to increased engulfment by host phagocytes, consistent with the lack of virulence of pbx mutants in animal models.

The basidiomycetous yeast Cryptococcus neoformans is ubiquitous in the environment and is most commonly associated with bird excreta (1–3). In recent years, this yeast has emerged as an important opportunistic pathogen of humans. Cryptococcosis poses a particular challenge in the developing world, where large populations of individuals are immunocompromised due to HIV infection in the context of limited health care resources. These factors contribute to a global death toll due to cryptococcal infection that was recently estimated to exceed 625,000 per year (4).

Cryptococcosis is initiated by inhalation of airborne infectious particles, either basidiospores or desiccated yeast cells (5). In healthy individuals, C. neoformans is either cleared or causes a latent infection, but in the context of immune compromise, this facultative intracellular pathogen can multiply and disseminate throughout the body; its ability to cross the blood-brain barrier leads to a frequently fatal meningoencephalitis (6).

The virulence of C. neoformans is attributed to multiple factors that include its ability to grow at human body temperature and inhibit phagocytosis; the secretion of proteases, phospholipase, and urease; melanin synthesis; and the elaboration of a polysaccharide cap (7–9). The capsule is a dynamic structure surrounding the cell wall that dramatically increases in thickness during infection, up to many times the cell radius. Capsule polysaccharide is also shed constitutively into the extracellular environment and impedes host responses to cryptococcal infection by inhibiting phagocytosis, altering antigen presentation, changing cytokine synthesis, and inhibiting leukocyte migration to the sites of inflammation (10).

The C. neoformans capsule is a complex structure composed of two high-molecular-mass polysaccharides, glucuronoxylomanan (GXM; ~90% of the mass) and glucuronoxylomannogalactan (GXMGal; ~7 to 8% of the mass), together with a small amount of mannoproteins (10–12). Purification of capsule polysaccharides shed from cryptococcal cells grown in vitro has enabled detailed structural studies of these components. GXM is a linear α-1,3-linked mannan of 1 to 7 MDa (13) whose mannose residues are variably O-acetylated and substituted with glucuronic acid and xylose (14). GXMGal is an α-1,6-galactan of roughly 100,000 Da. Alternate galactose residues of the linear backbone are branched with short side chains of galactose and mannose, which may be further substituted with xylose and glucuronic acid (15, 16); the branching backbone residues may be additionally substituted with galactofuranose (17) (other residues are all of the pyranose form). Both of the capsule polysaccharides demonstrate structural heterogeneity, depending on the strain and growth conditions (18, 19), and both have been implicated in cryptococcal pathogenesis (20, 21).

The synthesis of capsule polysaccharides and construction of the capsule involve multiple steps and significant metabolic investment (12, 22, 23). We previously reported that capsule polysaccharide synthesis occurs intracellularly, with the products subsequently being transported to the cell surface via elements of the protein secretory pathway (24). Once capsule polysaccharides exit the cell, they become associated with its surface (25). Little is known about the specific mechanisms of this interaction, although we have shown that it depends on cell wall α-1,3-glucan

Received 7 November 2013 Accepted 22 February 2014
Published ahead of print 28 February 2014
Address correspondence to Tamara L. Doering, doering@borcim.wustl.edu.
Supplemental material for this article may be found at http://dx.doi.org/10.1128/EC.00290-13.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/EC.00290-13
MATERIALS AND METHODS

Reagents. Difco medium components were from BD (Becton, Dickinson and Company, Sparks, MD), DNA polymerases (Taq and AccuPrime Pfu) and Escherichia coli DH5α competent cells were from Invitrogen (by Life Technologies Corporation), oligonucleotides were from Invitrogen or Sigma-Aldrich Co. LLC (St. Louis, MO), reagents for DNA isolation and biologic transformation were from Bio-Rad Laboratories Inc., and restriction enzymes were from Invitrogen or New England Biolabs Inc. Kits for purification of DNA fragments and PCR products were from Qiagen, In-Fusion HD cloning kits were from Clontech Laboratories Inc., nourseothricin (ClonNat) was from Werner BioAgents (Germany), and G418 (Geneticin) was from Invitrogen. Specialty reagents for electron microscopy were from Polysciences Inc. or Ted Pella Inc., and colloidal tin, ammonium sulfate, 0.15% [wt/vol] asparagine, 2% [wt/vol] glucose, 12 mM NaHCO3, 35 mM MOPS [morpholinepropanesulfonic acid], and 0.15% [wt/vol] NaCl were from Sigma. Murine monoclonal anti-GXM antibodies 3C2 and 2H1 were generated in our laboratory. The coding sequences of PBX1 and PBX2 were from Gary Cox, Duke University Medical Center. Luciferase assays were performed using AlkPhos direct labeling and detection system with a CDP-Star kit (GE Healthcare) according to the manufacturer’s instructions. Ten-microgram aliquots of genomic DNA from WT C. neoformans and from the independent ΔPBX1 and ΔPBX2 mutants were digested with HindIII and XhoI (which cuts within the PBX1-coding sequence but not that of the G418 resistance cassette) or BamHI and PvuII (which cuts within the PBX2-coding sequence but not that of the nourseothricin resistance cassette) and blotted using standard techniques (40) with probes corresponding to the 5’ or 3’ flanking regions of the PBX1 and PBX2 genes. These blots confirmed the gene replacement and that the marker cassette was present only in the genome with no additional ectopic sequences, including the upstream flank of each gene of interest with the 3’ part of the marker.

To identify additional factors involved in capsule assembly, we screened mutant cryptococcii using a capsule transfer assay. This assay is based on the observation that exogenous capsule polysaccharide, such as the material shed from wild-type cells, is able to bind to the surfaces of acapsular mutant strains of C. neoformans (e.g., the cap59Δ mutant) (26, 30). We tested a library of cryptococcal deletion mutants (31) for their display of surface capsule and their ability to serve as capsule donors in this transfer assay. Strains lacking the genes PBX1 and PBX2 showed defects in both surface capsule and capsule transfer in our screen. It has previously been reported that these mutants have reduced virulence in mice (32), highlighting the importance of investigating the function of the encoded proteins. We found that these mutants additionally exhibit morphological defects, reduced capsule synthesis and association, and increased uptake by mammalian phagocytes. We hypothesize that the Pbx proteins act at the membrane in cell wall remodeling, such that their absence leads to this constellation of phenotypes.

Culture conditions and strains. C. neoformans strains were stored at −80°C in 25% glycerol and streaked onto yeast extract peptone dextrose (YPD) agar (1% [wt/vol] yeast extract, 2% [wt/vol] peptone, 2% [wt/vol] dextrose, 2% agar) plates for growth at 30°C. Liquid cultures were grown at 30°C with shaking at 230 rpm in YPD broth or in capsule induction system with a CDP-Star kit (GE Healthcare) according to the manufacturer’s instructions. Ten-microgram aliquots of genomic DNA from WT, cap59Δ and three independent pbx1Δ and pbx2Δ mutants were digested with HindIII and XhoI (which cuts within the PBX1-coding sequence but not that of the G418 resistance cassette) or BamHI and PvuII (which cuts within the PBX2-coding sequence but not that of the nourseothricin resistance cassette) and blotted using standard techniques (40) with probes corresponding to the 5’ or 3’ flanking regions of the PBX1 and PBX2 genes. These blots confirmed the gene replacement and that the marker cassette was present only in the genome with no additional ectopic insertions (data not shown). The same approach was used to delete PBX1 and PBX2 in the cap59Δ mutant background for use in GXMGal isolation (see below). A pbx double mutant was also generated by deleting PBX2 (as above) in a pbx1Δ mutant strain.

To reconstitute confirmed pbx1Δ and pbx2Δ mutants, wild-type PBX sequences, including −1-kb flanking regions at both ends, were amplified. PCR was used to incorporate sequences for nourseothricin and G418 into these plasmids.
resistance after the 3' ends of the PBX1 and PBX2 ampcions, respectively, followed by another ~1 kb of appropriate 3' flanking sequence (details are available on request). Bioinformatic transformation was then carried out using a gene replacement strategy (similar to that described above) to incorporate the PBX sequences at their original loci.

**Epitope tagging of PbX1 and PbX2.** To episomally express tagged PbX proteins, we constructed plasmids in which the PBX1 and PBX2 genes were modified by the addition of a sequence encoding a triple hemagglutinin (HA) epitope tag at the 3' end. Briefly, an empty expression cassette was first assembled by PCR amplifying the ACT1 promoter and TRP1 terminator regions from *C. neoformans* KN99α genomic DNA using primers MSPC114 and MSPC115 and primers MSPC116 and MSPC117, respectively (primer sequences are provided in Table S1 in the supplemental material). The resulting ampcions were then fused by overlap PCR, using 5' phosphorylated primers, to a synthetic spacer consisting of PmlII and Mrel restriction sites, three copies of the HA sequence, and a plasmid pGMC200 (38) using PmeI and EcoRI and ligated to the PsiI and respectively (primer sequences are provided in Table S1 in the supplemental material). The resulting ampcions were then used to replace the corresponding regions of plasmid pMII and Mrel restriction sites, three copies of the HA sequence, and a stop codon. For drug selection, a fragment encoding the cryptococcal PmlII and MreI restriction sites, three copies of the HA sequence, and a plasmid pGMC200 (38) using PmeI and EcoRI and ligated to the PsiI and respectively (primer sequences are provided in Table S1 in the supplemental material).

**Capsule tagging.** A gene replacement strategy (similar to that described above) was used to incorporate the three copies of the HA tag in pMSC-043 to incorporate the three copies of the HA tag in the region of each coding sequence before the stop codon. The resulting ampcions were used to transform *C. neoformans* KN99α genomic DNA using primers PK201 and PK202 and primers PK203 and PK204, respectively, thereby incorporating PmlII and Mrel restriction sites. The products were digested with PmlII and Mrel and ligated to the corresponding sites of plasmid pMSC-043 to incorporate the three copies of the HA tag in frame with the 3' end of each coding sequence before the stop codon. The resulting ampcions, pPBX1-HA and pPBX2-HA, respectively, were transformed into DH5α cells for sequence confirmation, and plasmids with correct sequences were used to transform *C. neoformans* KN99α by electroporation for epitope expression. To do this, 3 × 10^6 cells in early log phase were transformed with 1 to 5 µg of DNA as described previously (42), with parameters set at 0.5 kV, 25 µF, and resistance of 1.000 Ω. Transformed cells were grown in liquid YPD for 2 h at 30°C and then plated for drug selection.

**Capsule transfer.** Capsule transfer assays were performed as described in reference 26, using the cap59A acapsular strain as the capsule acceptor and conditioned medium (CM) from 5-day-old cultures of KN99α or other indicated strains as the capsule donor. Accepting cells were grown overnight, harvested by centrifugation, and washed twice with phosphate-buffered saline (PBS). Cells (5 × 10^8) were diluted to 499 µl with PBS, mixed with 1 µl CM (or medium control), and rotated for 1 h at room temperature (RT). After transfer, the acceptor cells were sedimented by centrifugation and washed twice with PBS. To visualize capsule acquisition by the acceptor cells, or endogenous capsule on other strains, the cells were further incubated for 1 h at RT with a final concentration of 8 µg/ml of anti-GXM antibody 3C2 that had been conjugated to a fluorophore (Cy3 monoreactive dye from GE Healthcare, used according to the manufacturer’s recommendations). Stained cells were washed twice with PBS, followed by dehydration in a graded series of ethanol and propylene oxide prior to embedding in Eponate 12 resin (Ted Pella Inc., Redding, CA). Sections of 90 nm were cut with a Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained with uranyl acetate and lead citrate, and viewed on a Jeol 1200EX transmission electron microscope (Jeol USA Inc., Peabody, MA).

For immunoelectron microscopy, cells were fixed in glutaraldehyde as described above, washed three times in 50 mM citrate buffer, pH 6.0, and resuspended in 1 ml of 40 mg/ml lysing enzymes (L1412; Sigma) in the same buffer to partially digest the cell wall. After 30 min of incubation at 30°C, cells were washed in 0.1 M phosphate buffer, pH 7.2, for 1 h at room temperature, washed in the same buffer, and postfixed in 1% osmium tetroxide (Polysciences Inc.) for 1 h. Samples were then rinsed in the same buffer, followed by dehydration in a graded series of ethanol and propylene oxide prior to embedding in Eponate 12 resin (Ted Pella Inc., Redding, CA). Sections of 90 nm were cut with a Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained with uranyl acetate and lead citrate, and viewed on a JEOL 1200EX transmission electron microscope (JEOL USA Inc., Peabody, MA).

**Capsule induction.** Overnight cultures of *C. neoformans* in YPD were harvested by centrifugation, washed twice with Dulbecco’s modified Eagle’s medium (DMEM), and resuspended at 2 × 10^6 cells/ml in DMEM. One milliliter of the suspension was incubated at 37°C with 5% CO2 for 36 h in a 24-well tissue culture plate. Cells were harvested by centrifugation, washed once with deionized water (dH2O), and resuspended in 1 ml dH2O. Eight microliters of the cell suspension was mixed with 2 µl of India ink stain, and 6 µl of the mixture was spotted on a microscope slide for bright-field image acquisition on a Zeiss Axioskop 2 MOT Plus wide-field fluorescence microscope. In some experiments, cells were sonicated for 10 s using a Fisher sonic demembranator at 35% output before India ink staining.

**Phenotypic assays.** To measure growth, cells were grown in YPD or CIM at 30°C or 37°C with shaking as described above. Samples were collected at regular intervals, and the cell number was assessed using a Celledometer Auto M10 automated cell counter (Nexcelom Bioscience). For plate assays, *C. neoformans* strains were grown to mid-log phase in YPD broth and diluted to 10^5 cells/ml, and five 10-fold serial dilutions were made. Five microliters of each dilution was spotted onto solid medium plates, which were incubated at 30°C, 37°C, or 39°C. The solid media tested included YPD containing NaCl (0.1, 0.5, or 1.2 M), SDS (0.01, 0.03, or 0.06%), caffeine (1.5, or 15 mM), Congo red dye (0.1 or 0.5% from a 4% stock solution prepared in 50% ethanol), or calcofluor white (0.5, 1.0, or 1.5 mg/ml). Growth on various carbon sources was checked on minimal medium (0.17% [wt/vol] yeast nitrogen base without amino acids and ammonium sulfate, 0.5% [wt/vol] ammonium sulfate, 2% [wt/vol] agar) containing 2% (wt/vol) of the desired carbon source (glucose, galactose, or xylose).

Melanin synthesis was assessed by growing cells on glucose-free asparagine agar plates (0.1% [wt/vol] t-asparagine, 0.05% [wt/vol] MgSO4, 0.3% [wt/vol] KH2PO4, 0.001% [wt/vol] thiamine, 1 mM t-3,4-dihydroxyphenylalanine [t-DOPA], 2% [wt/vol] Bacto acto) in the dark at 30°C, 37°C, or 39°C and examining them on days 2 through 5 for melanization, seen as a brown colony color. To compare melanin retention in KN99 and mutant cell walls, cells grown overnight in the same medium without agar were collected, washed once in the same medium, and counted. Cells (10^6) were inoculated into 2 ml of fresh medium in 10-ml culture tubes in triplicate and shaken at 30°C for 24 h. Following incubation, the culture tubes were centrifuged at 3,000 × g for 10 min and photographed to visualize the cell wall-associated melanin in the cell pellet; the optical density at 400 nm of the supernatant fraction was also recorded to assess melanin release from the cells into the growth medium (34).

**Electron microscopy.** Overnight cultures were diluted to 2 × 10^6 cells/ml in YPD, grown for 9 h at 30°C, collected by centrifugation, quickly resuspended in 1 ml of primary fixation mix (0.1 M sorbitol, 1 mM MgCl2, 1 mM CaCl2, 2% glutaraldehyde in 0.1 M PIPES [piperazine-N,N'-bis(2-ethanesulfonic acid)] buffer, pH 6.8 [43]), and fixed overnight at 4°C. For ultrastructural analysis, cells were fixed in 2% glutaraldehyde (Polycomes Inc., Warrington, PA) in 100 mM phosphate buffer, pH 7.2, for 1 h at room temperature, washed in the same buffer, and postfixed in 1% osmium tetroxide (Polysciences Inc.) for 1 h. Samples were then rinsed in the same buffer, followed by dehydration in a graded series of ethanol and propylene oxide prior to embedding in Eponate 12 resin (Ted Pella Inc., Redding, CA). Sections of 90 nm were cut with a Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained with uranyl acetate and lead citrate, and viewed on a JEOL 1200EX transmission electron microscope (JEOL USA Inc., Peabody, MA).

For immunoelectron microscopy, cells were fixed in glutaraldehyde as described above, washed three times in 50 mM citrate buffer, pH 6.0, and resuspended in 1 ml of 40 mg/ml lysing enzymes (L1412; Sigma) in the same buffer to partially digest the cell wall. After 30 min of incubation at 30°C, cells were washed in 0.1 M phosphate buffer and postfixed, and blocks were prepared as described above. Sections were blocked for 30 min with a solution of 5% fetal bovine serum in 100 mM PIPES buffer (pH 7.0), labeled for 1 h with an anti-GXM monoclonal antibody (2H1), washed in blocking buffer, and incubated with 12-nm gold-conjugated goat anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories Inc., West Grove, PA). Sections were then washed once in 100 mM PIPES buffer, pH 7.0, and twice in dH2O, stained with uranyl acetate and lead citrate, and viewed as described above.

**Purification of GXM.** For GXM purification, cells were inoculated into 200 ml of CIM and grown for 5 days at 30°C with shaking. The cultures were autoclaved and centrifuged at 18,000 × g for 1 h at RT, and the supernatant fraction was filtered through a 0.22-µm-pore-size mem-
brane filter and used for GXM purification. Purification, based on precipitation of the negatively charged GXM with the cationic detergent cetyltrimethylammonium bromide (CTAB), was performed as described previously (22, 44).

**Purification of GXMGal.** GXMGal was purified following the procedure described for the serotype D cap5ΩΔ mutant strain (16, 22). YPD medium (200 ml) was inoculated with the cap5ΩΔ pbsxΩΔ, or cap5ΩΔ pbsxΔ mutant strain and incubated at 30°C with shaking for 5 days. Cells were sedimented (8,000 × g, 10 min, RT), and the supernatant fraction was concentrated to ~10 ml with a Pall Jumbosep spin concentrator containing a 10-kDa-molecular-weight- cutoff membrane. The concentrated supernatant was used to isolate GXMGal as described by Vaishnav et al. (16) and Klutts and Doering (22) using a combination of affinity, anion exchange, and size exclusion chromatography techniques.

**NMR spectroscopy.** Nuclear magnetic resonance (NMR) studies of GXM and GXMGal samples were performed as previously described (15, 22). GXM samples were dissolved in water at 5 mg/ml, sonicated to reduce the molecular mass, and deactylated by adjusting the pH to 11 with concentrated NH₄OH before incubation for 24 h at 25°C. Samples were then dialyzed, lyophilized, deuterium exchanged by lyophilization from D₂O, and dissolved in 0.7 ml D₂O for analysis. Proton, gradient-enhanced correlated spectroscopy (gCOSY), total correlation spectroscopy (TOCSY), heteronuclear single quantum correlation (HSQC), gradient-enhanced heteronuclear multiple-bond correlation (gHMBC), and nuclear Overhauser effect spectroscopy (NOESY) NMR spectra were acquired on a Varian Inova 500-MHz spectrometer at 70°C using standard Varian pulse sequences. TOCSY and NOESY mixing times were 120 and 300 ms, respectively. GXMGal samples were deuterium exchanged by dissolving the samples in D₂O and lyophilization, before dissolving the samples in 0.27 ml D₂O. One-dimensional proton spectra and two-dimensional gCOSY, TOCSY, NOESY, gHSQC, and gHMBC spectra were obtained on a Varian Inova 500-MHz spectrometer at 70°C using standard Varian pulse sequences. Proton chemical shifts were measured relative to the location of internal acetone (δH = 2.218 ppm, δC = 33.3 ppm). The relative molar amounts of GXM structural motifs were determined from the anomeric protons of the mannone residues after Lorentz-Gauss resolution enhancement of the proton spectra and deconvolution of the anomeric signals by use of the line-fitting routine in Mestre-C NMR software. The areas of the three peaks belonging to the same triad were averaged.

**GXMGal composition.** The glycosyl composition of GXMGal was analyzed by combined gas chromatography (GC)-mass spectrometry (MS) of the per-O-trimethylsilyl (TMS) derivatives of the monosaccharide methyl glycosides produced from the sample by acid methanolation as previously described (45, 46). GXMGal samples were dissolved in water, 20 μg of inositol was added as an internal standard, and the solutions were transferred to screw-cap glass tubes and freeze-dried. Methyl glycosides were prepared by heating the samples in 1 M methanolic HCl at 80°C, 18 h), followed by re-N-acetylation with pyridine and acetic anhydride in methanol (for detection of amino sugars). The samples were then per-O-trimethylsilylated by treatment with Tri-Sil reagent (Pierce) at 80°C (0.5 h). GC-MS analysis of the TMS methyl glycosides was performed both on an AT 7890N GC interfaced to a 5975C MSD system (electron impact ionization mode) and on a Shimadzu GCMS QP 1010 plus apparatus (chemical ionization mode); separation was performed on a Grace EC-1 bonded-phase fused-silica capillary column.

**GXM molecular mass determination.** The molecular masses of GXM were determined by multilateral light scattering (MALS) as described previously (13, 47). The dn/dc constant for GXM (change in the refraction index of the GXM solution with the change in the GXM concentration) was determined using an Optilab rEX refractive index detector (Wyatt Technology Corporation) in batch mode at 25°C. The instrument was precalibrated in MALS buffer (150 mM sodium chloride, 20 mM HEPES [pH 7.4], 0.01% sodium azide), and solutions prepared from anhydrous NaCl (0 [blank], 0.1, 0.5, 1.0, 1.2, 2.0, 3.0, 4.0, and 5.0 mg/ml) were loaded as standards for dn/dc constant determination (0.172 ml/g for NaCl at 690 nm). GXM samples were then prepared in the same buffer, mixed overnight, and filtered through 0.8-μm-pore-size syringe filters. The carbohydrate concentration was determined by phenol sulfuric acid assay (48), and 50, 100, 200, 300, 400, or 500 μg/ml of GXM was loaded onto the differential refractometer. The Astra V macromolecular characterization software package (Wyatt Technology Corporation) was used to calculate the dn/dc constant.

GXM samples in MALS buffer were loaded onto a size exclusion chromatography column (pore size, 300 Å; WTC-030S5; Wyatt Technology Corporation) set up in series with a Dawn Helios II multilangle light-scattering detector (Wyatt), an Optilab rEX differential refractive index detector (Wyatt), and a 996 photodiode array detector (Waters). The data were recorded for light scattering, refractive index change, and UV absorbance over the elution profile of GXM, and results were analyzed with the Astra V macromolecular characterization software package (Wyatt) to calculate the molecular mass from the light scattering and refractive index change.

**GXM immunoblotting.** Immunoblotting of GXM was performed essentially as we have previously reported (49). Briefly, 50 μl of CM from the indicated strains grown in YPD or CIM or 10 μg of GXM purified from CM of cells grown in CIM was mixed with 6× DNA loading dye, and the mixture was loaded on a 0.6% certified megabase agarose gel (Bio-Rad Laboratories Inc.) and subjected to electrophoresis for 15 h at 25 V in 0.5× TBE (44.5 mM Tris base, 44.5 mM boric acid, 1 mM EDTA, pH 8.3). The gel was transferred onto a positively charged nylon membrane and immunoblotted with 1 μg/ml anti-GXM antibody 3C2 as described in reference 49.

**Protein purification and localization.** Protein purification was performed at 4°C using a previously described method (50) with some modifications. Cells were grown overnight in 50 ml of YPD to late log phase, harvested by centrifugation (3,000 × g, 10 min, RT), washed once with cold Triton-EDTA buffer (100 mM Tris-HCl, pH 7.5, 0.1 mM EDTA), and resuspended in an equal volume of the same buffer containing protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride and protease inhibitor cocktail [10 μl/ml; P8215; Sigma]). All subsequent steps were performed at 4°C. Aliquots (800 μl) were transferred to 2-ml screw-cap microcentrifuge tubes and mixed with an equal volume of 0.5-mm glass beads (Bio-Spec Products), and the samples were subjected to 1-min bursts on a Mini-BeadBeater (BioSpec Products) alternating with 2 min on ice. Eight to 10 cycles of bead beating were required to disrupt ~75% of the cells (as assessed by microscopy). The lysate was then transferred to a 1.5-ml conical tube, the glass beads were rinsed twice with 800 μl of Tris-EDTA buffer, and both rinses were pooled with the lysate. The pooled material (total protein) was subjected to a low-speed clearing centrifugation step (1,000 × g, 25 min). The resulting cell-free supernatant fraction (S1; cytosol and membranes) was removed, and the pellet (P1) was stored at 4°C for later extraction. S1 was next fractionated by ultracentrifugation (60,000 × g, 45 min); the supernatant fraction from this step (S2; cytosol) was reserved, and the pellet (P2; total membranes) was resuspended in 200 μl of Tris buffer (100 mM Tris-HCl, pH 7.5) for detergent extraction of membrane proteins (see below). Protein concentrations were determined using a protein assay kit (catalog no. 5000006; Bio-Rad Laboratories Inc.).

For Triton X-100 (TX-100) extraction of membrane proteins, P2 was extracted with 1% TX-100 on ice for 1 h with brief vortex mixing every 5 min. Particulate material was removed by ultracentrifugation (60,000 × g, 45 min), and both the pellet (TX-100-insoluble) and supernatant (TX-100-soluble) fractions were stored at 4°C. A parallel P2 sample was extracted with 1% SDS by boiling for 10 min, after which the sample was centrifuged (15,000 × g, 10 min, RT) and the supernatant and pellet were saved as SDS-soluble and SDS-insoluble fractions, respectively. Detergent was removed by using an SDS-PAGE cleanup kit (GE Healthcare) before protein gel electrophoresis. The cell-wall-associated proteins were extracted as described in reference 51. Briefly, fraction P1 (see above) was resuspended in 1 ml of Trits buffer and disrupted by probe sonication (S...
cycles of 10 s on and 10 s off; output, 35%). The sample was then centrifuged at 3,500 × g for 10 min, and the pellet was washed three times with Tris buffer, resuspended in 1 ml of lysing enzyme (20 mg/ml in diH2O with protease inhibitors, as described above; L1412; Sigma), and rotated at 37°C for 1 h. After digestion, the sample was centrifuged at 15,000 g for 10 min, and the supernatant was preserved as cell wall-extracted proteins.

**Macrophage phagocytosis assay.** To measure uptake by macrophages, we used our previously published assay (52) with minor modifications. As host cells we used the human monocytic cell line THP-1, which was seeded onto 12-mm coverslips at a density of 2.5 × 10⁵ cells/ml in medium containing 0.2 μg/ml of phorbol myristate acetate (PMA) to induce differentiation. After 48 h, the medium was replaced with fresh medium containing 0.2 μg/ml of phorbol myristate acetate (PMA) to induce differentiation. After 48 h, the medium was replaced with fresh medium containing 0.2 μg/ml of phorbol myristate acetate (PMA) to induce differentiation.

**RESULTS**

**Screening for capsule mutants.** Our previous work showed that cell wall α-glucan is required for capsule association with *C. neoformans* cells (26, 27). We hypothesize that additional cellular elements are also required for the normal display of capsule on the cell surface. To identify such factors and further define the mechanism of capsule association in *C. neoformans*, we used a forward genetic approach, screening for mutants defective in either surface capsule display or the ability to donate capsule material to acapsular acceptor cells.

We tested surface capsule by labeling cryptococcal cells with an anti-GXM monoclonal antibody (3C2, kindly provided by Tom Kozel) and observing them by immunofluorescence microscopy (see Materials and Methods). As shown in Fig. 1 (left two columns), this antibody binds evenly to the cell surface of wild-type cells but does not label strains known to be acapsular (such as cap59Δ or ags1Δ mutants). We tested the ability of cryptococci to donate capsule (26) by collecting conditioned medium (CM) from cultures of the strains of interest and incubating it with cells of the acapsular cap59Δ mutant. We then washed the acceptor cells and used the 3C2 antibody to assess their acquisition of capsule material from the donor CM (see Materials and Methods). CM from wild-type cells was an effective donor of capsule material to the cap59Δ mutant in this assay, while CM from the cap59Δ mutant itself could not act as a donor (Fig. 1, right two columns). CM from cells of the ags1Δ mutant was transfer competent, although the mutant itself bore no capsule, showing that the defect in the ags1Δ mutant is one of capsule association with the cell surface, rather than a problem with capsule synthesis or release (Fig. 1) (27).

We screened the 1,201 strains in a *C. neoformans* deletion collection generated by the Madhani laboratory (31) and identified 13 with consistent differences in surface capsule or capsule transfer compared with wild-type *C. neoformans* (Table 2 and data not shown). Four known acapsular mutants, the CAP10, CAP59, CAP60, and CAP64 mutants, were negative for surface capsule, as shown previously (53–56), and for the ability to donate capsule material. A similar profile was seen in cells lacking an enzyme (Ugd1) required for the production of UDP-glucuronic acid and UDP-xylene; these molecules are important sugar donors for capsule polysaccharide synthesis (57–59). Several other mutants showed partial defects in the ability to donate capsule or in their surface capsule, but we were particularly interested in three strains that bore a surface capsule, as detected by antibody staining, but were not able to donate capsule in our transfer assay (Table 2, bold font). This phenotype was opposite that of the ags1Δ mutant cells, which do not display surface capsule but do shed capsule that can bind normally to acapsular cells (26). It suggested that these mutants (Table 2, bold font) made polysaccharide that could associate with the cells of origin but had some defect that precluded appreciable binding to acapsular cells. Findings for one of these mutants, the cpl1Δ mutant, will be presented elsewhere (Meng Yang and Tamara L. Doering, unpublished data). Below we present our findings on the other two mutants, the pbx1Δ and pbx2Δ mutants.

In previous studies of the pbx1Δ and pbx2Δ mutants, the miss-

![Cell surface capsule and capsule transfer](figure)

**FIG 1** Detection of cell surface capsule and capsule transfer. (Left two columns) Endogenous surface capsule of the indicated strains was probed by staining with the anti-GXM monoclonal antibody 3C2. (Right two columns) The cap59Δ capsular strain was used as the acceptor for exogenous capsule from CM of the indicated strains, washed, and stained similarly. The left panel of each pair is a differential interference contrast (DIC) image, and the right panel is an immunofluorescence (IF) image. All images are at the same magnification. Bar = 5 μm.

| Locus deleted | Protein encoded | Cell surface capsule | Capsule donor |
|---------------|-----------------|----------------------|---------------|
| None          |                 | +                    | +             |
| 02628         | Cap10           | –                    | –             |
| 00721         | Cap59           | –                    | –             |
| 00600         | Cap60           | –                    | –             |
| 02885         | Cap64           | –                    | –             |
| 04969         | Ugd1            | –                    | –             |
| 06813         | Cap1            | –/+                  | –/+           |
| 00440         | Sn801           | +                    | –/+           |
| 06889         | Na/H antiporter | +                    | –/+           |
| 06902         | Hypothetical    | +                    | –/+           |
| 05258         | Hypothetical    | +                    | –/+           |
| 02797         | Cpl1            | +                    | –             |
| 01172         | Pbxl            | +                    | –             |
| 05562         | Pbxs            | +                    | –             |
| 03120         | Ags1            | +                    | –             |

*CNAG, *Cryptococcus neoformans* assigned gene number (see http://www.broadinstitute.org/annotation/genome/cryptococcus_neoformans).*
ing proteins were implicated in capsule synthesis (32), although capsule transfer was not assessed at that time (see Discussion). To further address their function, we first replaced PBX1 and PBX2 in the serotype A strain KN99α with sequences that confer resistance to G418 and nourseothricin, respectively (37, 38). KN99α is closely related to the strain that was used to generate the mutant library (H99) but is more genetically tractable (33). We confirmed the new mutant strains (Table 1) by PCR and DNA blotting (data not shown) and tested them for surface capsule: as expected from our screen results, anti-GXM antibody staining of both mutants was similar to that of wild-type cells (Fig. 2A). Also consistent with our earlier results, CM harvested from cultures of the pbx1Δ or pbx2Δ mutant failed to donate capsule to the cap59Δ mutant; the same result was obtained with a double mutant (the pbx1Δ pbx2Δ mutant) that we generated by deleting the PBX2 gene in a pbx1Δ mutant background (Fig. 2A, left two columns). Complementation of the mutants by reintroduction of the wild-type sequences (pbx1Δ::PBX1 and pbx2Δ::PBX2) restored normal capsule transfer (Fig. 2B, right two columns).

**GXM release.** We wondered whether the inability of cells lacking Pbx1 and Pbx2 to act as capsule donors was due to the nature or amount of shed GXM. To test this, we performed standard capsule transfer assays in the presence of increasing concentrations of CM. At the standard CM dilution of 1:500, we observed no transfer of polysaccharide from mutant CM to acapsular acceptor cells, although wild-type CM showed a robust signal at this dilution (Fig. 3); similar results were obtained with a 1:20 dilution of CM. Notably, use of undiluted CM did result in transfer to cap59Δ mutant cells, although the capsule staining of the acceptor cells was not as complete as that with wild-type CM, demonstrated by an uneven and patchy signal (Fig. 3). These studies showed that mutant capsule could bind to acapsular cells, albeit poorly, but did not establish whether the underlying defect was a reduced amount of shed GXM in the CM or a reduced affinity of the polysaccharide material for the acapsular acceptor cells due to some fundamental change.

To directly examine the GXM that was shed from pbx mutant cells, we compared the polysaccharide-containing CM from each single mutant to that from the wild type by resolving the material on agarose gels and immunoblotting with anti-GXM 3C2 antibody (49). CM from the pbx mutant strains contained minimal antibody-reactive material compared to that from equal volumes of wild-type CM (Fig. 4, left). This material could be detected only on long exposures of the immunoblots (see Fig. S2 in the supplemental material). Similar analysis of CM from cultures grown in capsule-inducing medium (see Materials and Methods) showed slightly more GXM in the mutant CM, although this amount was still significantly less than that seen in wild-type CM (Fig. 4, center). (The growth rates of all strains were comparable in both media; see Fig. S3 in the supplemental material.) Because this analysis was based on antibody detection, we considered the possibility that the reduced signal might reflect altered interactions of mutant GXM with the 3C2 antibody. To test this, we purified GXM from each strain and compared equivalent mass amounts in a parallel blotting experiment. In this study, the GXM from all strains appeared to be identical in both signal intensity and gel migration behavior (Fig. 4, right). Furthermore, the purified GXM from each mutant showed the same efficacy as a capsule donor as wild-type purified GXM when comparable masses were included in transfer assays (not shown). Together, these experiments suggest that the poor function of pbx mutants as capsule donors does not reflect a difference in their GXM size (as assessed by gel electrophoresis) or structure (as assessed by antibody reactivity) but, rather, reflects a reduction in the amount of polysaccharide.

**FIG 2** pbxΔ strains display cell surface capsule but cannot donate capsule to acapsular acceptor cells in standard assays. (A) Surface capsule. Cells of the indicated strains were labeled with antibody 3C2 and imaged as described in the legend to Fig. 1. (B) Capsule transfer. CM from the indicated strains (or YPD alone as a control) was used as the capsule donor in transfer assays, with the cap59Δ mutant as the acceptor strain. Imaging is as described in the legend to Fig. 1. 1Δ, pbx1Δ mutant; 2Δ, pbx2Δ mutant; 1Δ:1, pbx1Δ mutant complemented with PBX1; 1Δ:2, pbx2Δ mutant complemented with PBX2; 1Δ:2Δ, pbx1Δ pbx2Δ mutant. All images in both panels are at the same magnification. Bar = 5 μm.
charide that is shed from the mutant cells during growth in culture.

Intracellular GXM. The observed reduced shedding of GXM could indicate either a defect in the production of this polysaccharide or a failure to release it into the medium. To distinguish between these possibilities, we probed thin sections of cryptococcal cells with a colloidal gold-tagged monoclonal antibody to GXM (2H1). The resulting immunoelectron micrographs (Fig. 5) showed abundant labeling of wild-type cell surfaces with occasional intracellular signal, especially on vesicular structures. In contrast, the \textit{pbx}1/\textit{H9004}, \textit{pbx}2/\textit{H9004}, and \textit{pbx}1/\textit{H9004} \textit{pbx}2/\textit{H9004} mutant strains showed less surface staining and no intracellular signal, consistent with a general reduction in GXM synthesis. Although reduced surface staining together with reduced shedding could also occur if the cells had a defect in secretion of capsule polysaccharide, we would expect such cells to demonstrate a corresponding increase in intracellular signal (24); the absence of any internal signal in the mutants, let alone such an increase (Fig. 5 and data not shown), further supports a defect in capsule polysaccharide synthesis.

Surface capsule. Our analysis of shed GXM (Fig. 4) suggested that the release of polysaccharides from \textit{pbx} mutants increased in capsule induction medium. To examine the induction of cell-associated capsule polysaccharides, we grew cells under inducing conditions (in DMEM with 5% CO\textsubscript{2} at 37°C; see Materials and Methods) and assessed capsule size by negative staining with India ink. Upon induction, all of the \textit{pbx} mutants produced capsules with a radius similar to that of the wild type (see the top row of Fig. S4 in the supplemental material), although the mutant capsules were more heterogeneous in thickness (data not shown). We further examined the capsule structure of cells grown under inducing conditions using quick-freeze deep-etch imaging. As we showed previously (25), the capsule fibers of wild-type cells grown in this way form a dense meshwork extending from the cell wall. In contrast, the \textit{pbx}1\textDelta, \textit{pbx}2\textDelta, and \textit{pbx}1\textDelta \textit{pbx}2\textDelta mutant strains showed less surface staining and no intracellular signal, consistent with a general reduction in GXM synthesis. Although reduced surface staining together with reduced shedding could also occur if the cells had a defect in secretion of capsule polysaccharide, we

FIG 4 \textit{pbx}\textDelta mutants are deficient in capsule shedding. Shown are the results of immunoblot analysis of CM or purified GXM from the indicated strains grown in rich medium (YPD) or CIM. Samples (50 \mu l of CM or 10 \mu g of GXM) were resolved by agarose gel electrophoresis and immunoblotted with antibody 3C2. The exposure time was 2 s (images after a longer exposure are shown in Fig. S2 in the supplemental material). The reduced migration of GXM from cells grown in CIM reflects the increased polymer size that results from capsule induction (49).

FIG 5 \textit{pbx}\textDelta mutants show reduced intracellular and surface capsule polysaccharide. Cryptococcal cells grown in YPD medium were examined by immunoelectron microscopy using colloidal gold-labeled anti-GXM monoclonal antibody 2H1. Each panel shows a portion of a cell of the indicated strain. All images are at the same scale. Bar = 500 nm.

FIG 6 The capsules of \textit{pbx}\textDelta mutants have reduced density. Quick-freeze, deep-etch electron micrographs for the indicated strains are shown. Each image shows a portion of the cell edge, with the plasma membrane at the top and capsule fibers at the bottom (extending downwards) separated by the cell wall. All strains were grown under the same conditions, and all images are at the same magnification. Bar = 100 nm.
does not), but the chemical structure of the mutant polysaccharide was not determined (32). To pursue this observation, we purified GXM from pbx1Δ mutant, pbx2Δ mutant, and wild-type cells for NMR analysis (see Tables S2 and S3 in the supplemental material). All three samples were composed of structures corresponding to mannolys triads M2 and M3 (Fig. 7), although the fraction of M3 was higher in the mutant strains than in the wild type (Table 3). This difference would correspond to an additional 25% of GXM reporter groups containing xylose β-1,4 linked to the backbone mannose residue that also bears glucuronic acid (ManA in Fig. 7), translating to an overall increase in GXM xylose of ~10%. We did not detect any glucose in the GXM structure (see Discussion).

To further characterize GXM purified from mutant and wild-type strains, we determined its molecular mass using multilangle light scattering (MALS). The masses of all three strains were very similar to each other (Table 4) and to the masses typical for serotype A strains (13). The slightly higher masses of the mutant GXM may reflect the presence of the modestly increased amount of xylose detected by NMR.

We also purified the second capsule polysaccharide, GXMGal, from wild-type and mutant strains of C. neoformans. For this study, we deleted PBX1 and PBX2 in a cap59Δ mutant background to avoid contamination of the GXMGal preparations with the more abundant GXM produced by wild-type cells. The compositions of mutant and wild-type GXMGal were very similar (Table 5), suggesting no alterations that could be attributed to the lack of Pbx proteins. We also used these samples for NMR determination of the GXMGal structure, as this has not been reported for acapsular serotype A strains. While the basic structure is similar to that reported for serotype D strains, the serotype A polymer contains more galactofuranose (data not shown) and exhibits more 2-acetylation of mannose residues (see Table S4 in the supplemental material). Overall, these studies suggested that the structures of both capsule polysaccharides in the pbx mutant strains are close to those of the wild type, although the amount of shed GXM is significantly reduced. These results are consistent with our observation that GXM purified from mutant strains binds normally to acapsular acceptor cells (not shown).

Cell wall analysis. Because the relatively modest differences in the capsule polysaccharide structure of the pbx mutants may not be enough to explain the defects in capsule association with the cell wall (revealed by sonication), we examined the latter structure more closely. Cell wall-perturbing agents such as SDS, calcineurin white, and Congo red did not alter the growth of the mutant compared to that of the wild type (data not shown), suggesting normal overall cell integrity. We also compared the morphology of mutant cells to that of wild-type cells. Although the mutants exhibited no alterations in the thickness or general appearance of the cell wall when assessed at high magnification by thin-section electron microscopy (not shown), lower-magnification views showed that the cells were less regular in shape than wild-type or complemented mutant cells. While most wild-type or complemented mutant cells were round and smooth surfaced, the mutants showed asymmetric and uneven boundaries (Fig. 8). In other phenotypic changes that are potentially related to the cell wall, the pbx1Δ, pbx2Δ, and pbx1Δ pbx2Δ mutants showed modest defects in the production of cell wall melanin, and the pbx1Δ pbx2Δ double mutant showed reduced production of mating filaments (see Fig. S5 and S6 in the supplemental material). These cells also displayed heightened sensitivity to oxidative stress (Fig. 9), which has been related to cell walls in yeasts (60, 61).

Pbx protein localization. The Pbx proteins are predicted to have transmembrane domains and localize to membranes (Fig. S8 in the supplemental material). Consistent with this, immunoblotting analysis of HA-tagged versions of Pbx1 and Pbx2 expressed in C. neoformans showed that both proteins were completely absent from the cytosolic fraction (Fig. 10). The proteins were not extracted from membranes by 1% Triton X-100 (4°C, 1 h), although they could be extracted with 1% SDS (100°C, 10 min), and they

![FIG 7 GXM structural motifs.](http://ec.asm.org/)

**TABLE 3 Molar ratios of the mannosyl triads detected in GXM from WT and mutant strains**

| Triad | Molar ratio | WT KN99 | pbx1Δ mutant | pbx2Δ mutant |
|-------|-------------|---------|--------------|---------------|
| M2    | 85          | 63      | 60           |               |
| M3    | 15          | 37      | 40           |               |

**TABLE 4 Molecular masses for purified GXM derived from MALS analysis**

| GXM source | dn/dc constant | Molecular mass (Da) |
|------------|----------------|---------------------|
| WT KN99    | 0.175          | 1.578 x 10^6        |
| pbx1Δ mutant | 0.157            | 1.635 x 10^6        |
| pbx2Δ mutant | 0.167            | 1.636 x 10^6        |

**TABLE 5 GXMGal glycosyl composition**

| Monosaccharide | cap59Δ mutant Mass (μg) | cap59Δ pbx1Δ mutant Mass (μg) | cap59Δ pbx2Δ mutant Mass (μg) |
|---------------|-------------------------|-------------------------------|-------------------------------|
| Xylose        | 72.6 15.5               | 278.5 12.9                   | 116.4 14.1                   |
| Glucuronic acid | 10.3 1.7                 | 101.5 3.6                     | 15.7 1.5                     |
| Mannose       | 122.0 21.7              | 576.8 22.3                   | 235.1 23.7                   |
| Galactose     | 342.4 61.0              | 1,580.3 61.1                 | 603.9 60.8                   |
| Total         | 547 100                 | 2,537.1 100                  | 971.2 100                    |
were not associated with cell wall fractions (Fig. 10). These characteristics suggest that they are located in detergent-resistant membranes (see Discussion).

**Host cell interaction.** Finally, we investigated the interactions of the pbx mutant strains with host phagocytes, which have been implicated in fungal latency and dissemination, in addition to host defense. We found that phagocyte engulfment of these strains was increased by about 50% compared to the level of internalization of wild-type cells (Fig. 11; \( P = 2.2 \times 10^{-10} \)). This may contribute to the reduced virulence of single pbx mutants that has previously been reported (32) (see Discussion).

**DISCUSSION**

The cell wall of *C. neoformans* is required for fungal integrity, and its polysaccharide capsule is critical for pathogenesis (12, 23, 62, 63). Although these two key structures are physically linked, the mechanism of their association is only poorly understood. In previous work, we developed a capsule transfer assay to assess the ability of capsule polysaccharides shed from donor cells to bind to the cell walls of acapsular mutant acceptor cells. This enabled us to identify cell wall α-glucan as an important attribute of the acceptor cell walls which was needed for cell surface display of capsule polysaccharides (26, 27). We hypothesized that characteristics of the donor cell would also contribute to this process. To identify such features, we screened a deletion collection generated by the Madhani group (31) for mutants that could not effectively func-
tion as capsule donors in our transfer assay. In parallel, we assessed the surface capsule of these strains.

Our screen identified several strains with an impaired ability to serve as capsule donors and two groups of mutants that were completely unable to do so. One of these groups included four Cap mutants that have previously been characterized to be acapsular (53–56), along with another strain that we previously showed has an acapsular phenotype (ugd1) (58). Our identification of these strains, which, as expected from the literature, also lacked surface capsule (Table 2), validated our screening approach.

A second group of interesting mutants included strains that were unable to serve as capsule donors, even though they did display surface capsule (Table 2). This report describes our find- ings on two of these strains, the p bx1Δ and p bx2Δ mutants, which have indistinguishable phenotypes. Compared to wild-type cells, both mutants have less dense arrays of capsule fibers and capsules that are more loosely associated with the cell wall. The p bx mu- tants also shed greatly reduced amounts of capsule compared to the wild type, which accounts for their transfer defect. This most likely reflects a global defect in synthesis, because capsule material within the cell and at the cell surface is also reduced (Fig. 5). Both p bx mutants also displayed an aberrant cell wall morphology and exhibited some mild phenotypes associated with cell wall dysfunc- tion that were more severe in the double mutant. p bx mutant cells were also engulfed more avidly than wild-type cells by human phagocytic cells, a process that has been implicated in host defense as well as fungal latency and dissemination. In some scenarios, residence within host cells may benefit C. neoformans. However, in the context of mutant cells that have deformed cell walls and increased sensitivity to oxidative stress, this engulfment is likely a dead end, and the increased phagocytosis may contribute to the observed virulence defect of cells lacking Pbx proteins (32).

P bx1 and P bx2 have parallel beta-helix domains, like cell wall-degrading enzymes such as pectin lyase, homogalacturonase, and xylloglucanase. Despite significant effort, we were unable to directly demonstrate glucanase activity for these proteins (see the text in the supplemental material). One possibility is that the P bx proteins act to remodel the cell wall, liberating sugars for other synthetic processes. According to this model, the cell wall would overgrow in the absence of P bx1 and P bx2 at the expense of capsule synthesis; the abnormal wall would also mediate looser associations with the capsule. This model is consistent with the phenotypes that we observed in the p bx mutants, including their aberrant morphology (Fig. 8), less dense capsules (Fig. 5) that are easily released from the cell surface (32) (see Fig. S4 in the supplemen- tal material), and a reduction in capsule shedding (Fig. 4) and the resultant transfer (Fig. 2 and 3). Based on the identical pheno- types of the two mutants and defects that were generally more severe in the double mutant, we believe that P bx1 and P bx2 serve redundant functions, although confirmation of this would require additional investigation.

In addition to the gross morphological changes in p bx mutant cell walls (Fig. 8), we observed several more subtle alterations suggesting cell wall abnormalities. The p bx1Δ and p bx2Δ mutants showed decreased production of melanin (see Fig. S5 in the supplemen- tal material), which occurs at the cell wall, and heightened binding of the cell wall stain lucifer yellow (data not shown). The double mutant was further defective in generating mating structures (see Fig. S6 in the supplemental material). Interestingly, none of the mutants differed from the wild type in sensitivity to calcofluor white and Congo red (not shown), two dyes typically used to assess cell wall integrity (64). Since these compounds bind with the highest affinity to chitin (65), this suggests that cell wall chitin is normal in the p bx mutants. Supporting this suggestion, these com- pounds and several other reagents that bind to related cellular components, including wheat germ agglutinin (N-acetylglucosamine), pontamime (chitin and chitosan), and eosin Y (chitosan), bind similarly to mutant and wild-type cells (not shown).

Additional support for our hypothesis that P bx proteins act in cell wall remodeling comes from their localization in detergent-resistant membranes (Fig. 10), also termed lipid rafts (66). There is significant precedent in fungi for membrane proteins playing critical roles in cell wall assembly and morphogenesis; examples include Saccharomyces cerevisiae, Neurospora crassa, and Aspergillus fumigatus (67–69).

Our model suggests that the absence of P bx proteins leads to reduced cell wall remodeling, which has consequences for cell morphology and capsule association. This would also alter the metabolic balance of the cells and the substrates available for synthesis of glycans, potentially explaining the reduced capsule polysaccharide synthesis of the p bx mutants. Metabolic imbalance might also explain the slightly increased xylosylation of the mu- tant capsule polysaccharide. Although xylose is incorporated into cryptococcal glycoproteins (70, 71), it is a relatively minor com- ponent of cryptococcal glycosaccharide structures (66), as is the case for the p bx mutants. The presence of cell wall glucans may have led to the previ-
ous observation of glucose in capsule polysaccharide samples from these strains.

We conclude that Pbx proteins act in C. neoformans cell wall remodeling. Their absence leads to an abnormal cell wall structure, which impairs capsule association, and altered metabolic balance, which reduces capsule polysaccharide synthesis. These changes yield cells that are less fit to cause disease, as demonstrated by their lack of virulence (32). Future work will be needed to demonstrate a specific biochemical function for these intriguing enzymes; this may require lipid reconstitution and further definition of cryptococcal glycans to suggest potential substrates. Nonetheless, our work has demonstrated the interplay between cell wall and capsule synthesis and elucidated how perturbations in these processes critically affect the virulence of this deadly pathogen.

ACKNOWLEDGMENTS

We are grateful to Meng Yang and Mike Skowrya for helpful discussions, Mike Skowrya for plasmid pMSC-043, Tom Kozel and Arturo Casadevall for monoclonal antibodies, Jennifer Lodge and Gary Cox for plasmids, Joe Heitman and Jennifer Lodge for strains, and Zhuo Wang and Lucy Li for monoclonal antibodies, Jennifer Lodge and Gary Cox for plasmids, Joe Heitman and Jennifer Lodge for strains, and Zhuo Wang and Lucy Li for comments on the manuscript. We also thank Barbara Kunkel and Andrew Mutka for help in establishing C. neoformans infections in Arabidopsis thaliana, Daved Fremont for use of MALDI equipment, Christopher Nelson for advice on GXM molecular weight determination, Wandy Beatty for performing thin-section microscopy, David Smith and Jamie Heimburg-Molinaro for glycan array analysis, Marcellene Hollingsworth and Tom Kozel for surface plasmon resonance studies of GXM binding, and Robyn Roth and John Heuser for quick-freeze deep-etch micrographs.

Work on cryptococcal glycan synthesis in the T. L. Doering lab was supported by NIH grant R01 GM071007, and polysaccharide analysis performed at the Complex Carbohydrate Research Center was supported by DOE grant DE-FG02-93ER20097. The Consortium for Functional Glycomics, which supported the glycan array studies at the Protein-Glycan Interaction Core at the Emory University School of Medicine and related compound synthesis at the Glycan Array Synthesis Core at the Scripps Research Institute, was funded by NIH grants GM062116 and GM098791. F.H.S.-T. was partially supported by NIH grant R01 AI78795 and a postdoctoral enrollment award for URM scientists from the Burroughs Wellcome Foundation.

REFERENCES

1. Casadevall A, Perfect JR (ed). 1998. Cryptococcus neoformans. ASM Press, Washington, DC.
2. Ellis DH, Pfeiffer TJ. 1990. Natural habitat of Cryptococcus neoformans var. gattii. J. Clin. Microbiol. 28:1642–1644.
3. Emmons CW. 1951. Isolation of Cryptococcus neoformans from soil. J. Bacteriol. 62:685–690.
4. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525–530. http://dx.doi.org/10.1097/QAD.0b013e32823282f1ac.
5. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (ed). 2011. Cryptococcus. From human pathogen to model yeast. ASM Press, Washington, DC.
6. Sabiti W, May RC. 2012. Mechanisms of infection by the human fungal pathogen Cryptococcus neoformans. Future Microbiol. 7:1297–1313. http://dx.doi.org/10.2217/fmb.12.102.
7. Buchanan KL, Murphy JW. 1998. What makes Cryptococcus neoformans a pathogen? Emerg. Infect. Dis. 4:71–83. http://dx.doi.org/10.3201/eid0401.980109.
8. Rodrigues ML, Alvarenga CS, Travassos LR. 1999. Pathogenicity of Cryptococcus neoformans: virulence factors and immunological mechanisms. Microbes Infect. 1:293–301. http://dx.doi.org/10.1016/S1286-4579(99)00025-2.
9. Chun CD, Brown JC, Madhani HD. 2011. A major role for capsule-independent phagocytosis-inhibitory mechanisms in mammalian infection by Cryptococcus neoformans. Cell Host Microbe 9:243–251. http://dx.doi.org/10.1016/j.chom.2011.02.003.
10. O’Meara TR, Alspaugh JA. 2012. The Cryptococcus neoformans capsule: a sword and a shield. Clin. Microbiol. Rev. 25:387–408. http://dx.doi.org/10.1128/CMR.00001-12.
11. Cherniak R. 1988. Soluble polysaccharides of Cryptococcus neoformans. Curr. Top. Med. Mycol. 2:30–54. http://dx.doi.org/10.1016/0796-1412(88)90012-2.
12. Doering TL. 2009. How sweet it is! Cell wall biogenesis and polysaccha-
ride capsule formation in Cryptococcus neoformans. Annu. Rev. Microbiol. 63:223–247. http://dx.doi.org/10.1146/annurev.micro.62.081307.162753.
13. McFadden DC, De Jesus M, Casadevall A. 2006. The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J. Biol. Chem. 281:18686–1875. http://dx.doi.org/10.1074/jbc.M509465200.
14. Cherniak R, Valafar H, Bistoni F, Leppla SH, Valafar F. 1998. Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic res-
onance spectra of glucuronoxylomannans with a computer-simulated art-
ificial neural network. Clin. Diagn. Lab. Immunol. 5:146–159.
15. Heiss C, Kluttis JS, Wang Z, Doering TL, Azadi P. 2009. The structure of Cryptococcus neoformans galactomannan contains beta-D-glucuronic acid. Carbohydr. Res. 344:915–920. http://dx.doi.org/10.1016/j.carres.2009.03.003.
16. Vaishnav VN, Bacon BE, O’Neill M, Cherniak R. 1998. Structural characterization of the galactomannan of Cryptococcus neoformans Cap67. Carbohydr. Res. 306:315–330. http://dx.doi.org/10.1016/S0008-6215(97)10058-1.
17. Heiss C, Skowrya ML, Liu H, Kluttis JS, Wang Z, Williams M, Srikanta D, Beverley SM, Azadi P, Doering TL. 2013. Unusual galactofuranose modification of a capsule polysaccharide in the pathogenic yeast Cryptococcus neoformans. J. Biol. Chem. 288:10994–11003. http://dx.doi.org/10.1074/jbc.M112.414998.
18. Azadi P, Yang M, Haynes BC, Skowyra ML, Doering TL. 2009. Pathogenicity of Cryptococcus neoformans from soil. J. Biol. Chem. 284:13427–13434. http://dx.doi.org/10.1074/jbc.M708927200.
19. Kumar P, Yang M, Haynes BG, Skowrya ML, Doering TL. 2011. Emerging themes in cryptococcal capsule synthesis. Curr. Opin. Struct. Biol. 21:597–602. http://dx.doi.org/10.1016/j.sbi.2011.08.006.
20. Yoneda A, Doering TL. 2006. A eukaryotic capsular polysaccharide is synthesized intracellularly and secreted via exocytosis. Mol. Biol. Cell 17:5131–5140. http://dx.doi.org/10.1091/mbc.E06-08-0701.
21. Pierini LM, Doering TL. 2001. Spatial and temporal sequence of capsule construction in Cryptococcus neoformans. Mol. Microbiol. 41:105–115. http://dx.doi.org/10.1046/j.1365-2958.2001.02504.x.
22. Doering TL, Doering JF. 2003. Cell wall alpha-1,3-glucan is required to anchor the Cryptococcus neoformans capsule. Mol. Microbiol. 50:1401–1409. http://dx.doi.org/10.1046/j.1365-2958.2003.03780.x.
23. Reese AJ, Yoneda A, Breger JA, Beauvais A, Liu H, Griffith CI, Bose I, Kim MJ, Skau C, Yang S, Selko JA, Osumi M, Latge JP, Mylonakis E, Doering TL. 2007. Loss of cell wall alpha-1 (3) glucan affects Cryptococcus neoformans from ultrastructure to virulence. Mol. Microbiol. 63:1385–1398. http://dx.doi.org/10.1111/j.1365-2958.2006.05511.x.
24. Fonseca FL, Nimmrichter L, Cordero RJ, Frases S, Rodrigues J, Goldman DL, Andruszakiewicz R, Milewski S, Travassos LR, Casadevall A, Ro-
grigues ML. 2009. Role for chitin and chitooligomers in the capsular architecture of Cryptococcus neoformans. Eukaryot. Cell 8:1543–1553. http://dx.doi.org/10.101128/EC.2009.03.004.
25. Rodrigues ML, Alvarez M, Fonseca FL, Casadevall A. 2008. Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of
36. Nelson Ashwell

48. Nielsen

51. Edman

Baker

34. Fu

45. Merkle

38. York

44. Sheng

43. Biondino

41. Ram

Gilbert

64. Reilly

68. Park

70. Roncero

69. Chang

67. Alvarez

65. Gilber

63. Park

62. Gesch

60. McDade

59. Wright

58. Wright

57. Wright

56. Wright

55. Wright

54. Wright

53. Wright

52. Wright

51. Wright

50. Wright

49. Wright

48. Wright

47. Wright

46. Wright

45. Wright

44. Wright

43. Wright

42. Wright

41. Wright

40. Wright

39. Wright

38. Wright

37. Wright

36. Wright

35. Wright

34. Wright

33. Wright

32. Wright

31. Wright

30. Wright

29. Wright

28. Wright

27. Wright

26. Wright

25. Wright

24. Wright

23. Wright

22. Wright

21. Wright

20. Wright

19. Wright

18. Wright

17. Wright

16. Wright

15. Wright

14. Wright

13. Wright

12. Wright

11. Wright

10. Wright

9. Wright

8. Wright

7. Wright

6. Wright

5. Wright

4. Wright

3. Wright

2. Wright

1. Wright

30. Srikanta D, Yang M, Williams M, Doering TL. 2011. A sensitive high-throughput assay for evaluating host-pathogen interactions in Cryptococcus neoformans infection. PLoS One 6:e22273. http://dx.doi.org/10.1371/journal.pone.0022773

31. Chang YC, Kwon-Chung KJ. 1994. Complementation of a capsule-deletion mutant of Cryptococcus neoformans restores its virulence. Mol. Cell. Biol. 14:4912–4919.

32. Chang YC, Kwon-Chung KJ. 1998. Isolation of the third capsule-associated gene, CAP60, required for virulence in Cryptococcus neoformans. Infect. Immun. 66:2230–2236.

33. Chang YC, Kwon-Chung KJ. 1999. Isolation, characterization, and localization of a capsule-associated gene, CAP10, of Cryptococcus neoformans. J. Bacteriol. 181:5636–5643.

34. Chang YC, Penoyer LA, Kwon-Chung KJ. 1996. The second capsule gene of Cryptococcus neoformans, CAP64, is essential for virulence. Infect. Immun. 64:1977–1983.

35. Bar-Peled M, Griffith CL, Ory JJ, Doering TL. 2004. Biosynthesis of UDP-GlcA, a key metabolite for capsule polysaccharide synthesis in the pathogenic fungus Cryptococcus neoformans. Biochem. J. 381:131–136. http://dx.doi.org/10.1042/BJ20031075.

36. Griffith CL, Klutsis JS, Zhang L, Levery SB, Doering TL. 2004. UDP-glucose dehydrogenase plays multiple roles in the biology of the pathogenic fungus Cryptococcus neoformans. J. Biol. Chem. 279:51669–51676. http://dx.doi.org/10.1074/jbc.M408889200.

37. Morey A, Janbon G. 2004. UGD1, encoding the Cryptococcus neoformans UDP-glucose dehydrogenase, is essential for growth at 37 degrees C and for capsule biosynthesis. Eukaryot. Cell 3:1601–1608. http://dx.doi.org/10.1128/EC.00146-08.

38. de Souza Pereira R, Geibel J. 1999. Direct observation of oxidative stress on the cell wall of Saccharomyces cerevisiae strains with atomic force microscopy. Mol. Cell. Biochem. 201:17–24. http://dx.doi.org/10.1023/A:1007704657.

39. Gerik KJ, Bhimireddy SR, Ryser JS, Specht CA, Lodge JK. 2008. PKC1 is essential for protection against both oxidative and nitrosative stresses, cell integrity, and normal manifestation of virulence factors in the pathogenic fungus Cryptococcus neoformans. Eukaryot. Cell 7:1685–1698. http://dx.doi.org/10.1128/EC.00146-08.

40. Baker LG, Specht CA, Lodge JK. 2011. Cell wall chitosan is necessary for virulence in the opportunistic pathogen Cryptococcus neoformans. Eukaryot. Cell 10:1264–1268. http://dx.doi.org/10.1128/EC.00307-07.

41. McDonald HG, Cox GM. 2008. Parallel Beta-Helix Proteins in C. neoformans. Annu. Rev. Plant Biol. 59:1007–1023. http://dx.doi.org/10.1146/annurev-plant-050312-120103.

42. Alvarez FJ, Douglas LM, Konopka JB. 2009. The Sur7 protein resides in punctate membrane subdomains and mediates spatial regulation of cell wall synthesis in Candida albicans. Commun. Integr. Biol. 2:76–77. http://dx.doi.org/10.4161/cib.2.1.9483.

43. Free SJ, 2013. Fungal cell wall organization and biosynthesis. Adv. Genet. 81:33–82. http://dx.doi.org/10.1016/B978-0-12-407677-8.00002-6.

44. Wang HX, Douglas LM, Aimiandia V, Latje JP, Konopka JB. 2011. The Candida albicans Sur7 protein is needed for proper synthesis of the fibrillar component of the cell wall that confers strength. Eukaryot. Cell 10:672–80. http://dx.doi.org/10.1128/EC.00167-10.

45. Reilly MC, Aoki K, Wang ZA, Skowyra ML, Williams M, Tiemeier M, Doering TL. 2011. A xylosylphosphotransferase of Cryptococcus neoformans acts in protein O-glycan synthesis. J. Biol. Chem. 286:26888–26899. http://dx.doi.org/10.1074/jbc.M111.262162.